Korea Investment CORP Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

Korea Investment CORP lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 32.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 141,077 shares of the medical research company’s stock after selling 67,955 shares during the period. Korea Investment CORP’s holdings in IQVIA were worth $27,723,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the period. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the fourth quarter valued at $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 1.2 %

IQV opened at $177.27 on Friday. The company has a market cap of $31.25 billion, a P/E ratio of 23.64, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $176.03 and a 12 month high of $253.84. The business’s 50-day moving average price is $193.15 and its 200-day moving average price is $206.47. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on IQV shares. Robert W. Baird lowered their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Truist Financial reissued a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.